» Authors » Raymond Coakley

Raymond Coakley

Explore the profile of Raymond Coakley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 35
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cristinziano M, Shashkina E, Chen L, Xiao J, Miller M, Doligalski C, et al.
Nat Commun . 2024 Nov; 15(1):10360. PMID: 39609405
Nontuberculous mycobacterium (NTM) infections are challenging to manage and are frequently non-responsive to aggressive but poorly-tolerated antibiotic therapies. Immunosuppressed lung transplant patients are susceptible to NTM infections and poor patient...
2.
Evans R, Walter K, Lobo L, Coakley R, Doligalski C
Clin Transplant . 2022 Jul; 36(8):e14770. PMID: 35801376
Background: Chronic lung allograft dysfunction (CLAD) remains the primary cause of death in lung transplant recipients (LTRs) despite improvements in immunosuppression management. Despite advances in knowledge regarding the pathogenesis of...
3.
Doligalski C, McKinzie C, Yang A, Lobo L, Coakley R
Pharmacotherapy . 2022 Jun; 42(7):580-584. PMID: 35689451
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a highly effective therapy for patients with cystic fibrosis (CF) with potential benefits in lung transplant recipients (LTRs) for extrapulmonary CF manifestations; however, tolerability and efficacy in...
4.
Abdullah L, Coakley R, Webster M, Zhu Y, Tarran R, Radicioni G, et al.
Am J Respir Crit Care Med . 2017 Nov; 197(4):481-491. PMID: 29099608
Rationale: Cystic fibrosis (CF) airways disease produces a mucoobstructive lung phenotype characterized by airways mucus plugging, epithelial mucous cell metaplasia/hyperplasia, chronic infection, and inflammation. Simultaneous biochemical and functional in vivo...